Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The association of ACE I/D polymorphism with the severity of COVID-19 in Iranian patients: A case-control study

Javad Soltani Rezaiezadeh a, Javad Safdari Lord a, Mir Saeed Yekaninejad b, Pantea Izadi a, b

a Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences and Health Services, Tehran, Islamic Republic of Iran
b Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences and Health Services, Tehran, Islamic Republic of Iran

1. Introduction

Following the outbreak of COVID-19 in 2019 in China and the onset of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, initial observations showed that patients with COVID-19 had symptom diversity (Wu et al., 2020). Even infected patients in a family showed a different phenotypic spectrum of the disease: asymptomatic, mild, severe symptoms (leading to hospitalization) and critical condition (requiring admission to intensive care unit and ventilator respiration as a lethal condition) (Yanes-Lane et al., 2020; Wu and McGoogan, 2020). Although some known risk factors (such as ages above 65 years, chronic respiratory diseases, hypertension, diabetes, etc.) predispose patients to the severe form of COVID-19, the cause of the disease severity is still not fully understood in some patients without these known underlying risk factors. Based on these observations, the researchers were looking for the role of genetic background on the severity of COVID-19 infection. Accordingly, several studies have investigated several candidate genes and single nucleotide polymorphisms (SNPs) that lead to differences in susceptibility to COVID-19 (Schurr, 2020; Kachuri et al., 2020; Smatti et al., 2020). However, the findings in different populations were inconclusive.

Regarding to the entrance mechanism of COVID-19 to the host cells, it seems that the polymorphisms of ACE1 gene may be influential in the disease severity. Angiotensin converting enzymes (ACE1/ACE2) are proteins of renin-angiotensin system (RAS) which play important role in regulation of blood pressure and fluid electrolyte balance (Zhou et al., 2020). It has been shown that the COVID-19 virus enters the human cells through the binding of the viral spike protein to ACE2 as a receptor on cell surface (Zhou et al., 2020). ACE2, is expressed in a variety of human organs and tissues and is a homolog of angiotensin-converting enzyme-1 (ACE1). ACE1 has a variety of biological activities and can counteract the negative role of the renin-angiotensin system in many diseases (Donoghue et al., 2000; Patel et al., 2017; Santos et al., 2018). On the other hand, ACE2 acts as a vaso dilator factor and modulates the effects of ACE1. These two enzymes have opposite effects to each other and ACE1/ACE2 balance will play an important role in the severity of coronary disease (Gemmati et al., 2020a). ACE1 encoding gene contains 26 exons and is located on chromosome 17q23.3 and also known as DCP, ACE1, DCP1, CD143 (OMIM number 106180). It encodes a key enzyme in the conversion of angiotensin I to angiotensin II (Tikhomirova et al., 2020).
development of severe and critical form of COVID-19, various risk factors such as old age, underlying medical conditions, male gender as well as comorbidities such as diabetes, hypertension, heart disease, obesity, chronic lung disease, immunodeficiency and cancers have been identified (Gao et al., 2021). Interestingly, many of these comorbidities are closely associated with ACE I/D polymorphisms and given the role of these polymorphisms in the ACE/ACE2 balance, it can be a genetic risk factor for severe COVID-19 infection (Yamamoto et al., 2021).

Accordingly, we tried to investigate the association between ACEI I/D polymorphism with susceptibility to severe form of COVID-19 infection in Iranian patients.

2. Materials and methods

2.1. Study population

From September to December 2020, two hundred and fifty-one COVID-19 patients referred to Farmanfarmayan Health center (Tehran, Iran) participated voluntarily in this study. All of the patients had positive COVID-19 RT-PCR test result for their nasopharyngeal swab samples. This study has been approved by the ethics committee of the school of medicine of Tehran University of Medical Sciences (Ethics code: IR.TUMS.MEDICINE.REC.1399.794). This study was also conducted in accordance with the Helsinki Declaration and all experiments and techniques used in this study have been performed in accordance with the relevant regulations. Blood samples were collected from all participants in EDTA-tubes as anticoagulant after signing informed consent form. Patients with asymptomatic or mild form of COVID-19 infection categorized as control group without age limitation (n = 151). Patients with severe to critical symptoms (such as a respiratory rate more than 30 beats per minute, oxygen saturation level (SPO2) less than 90%, lung infiltration more than 50% and organ failure), who also needed to be hospitalized were classified as case group (n = 100). Since our study design was based on the exclusion of known confounding factors for the association of ACE polymorphism with the disease severity (such as ages older than 65 years and underlying diseases predisposing to severe symptoms), all patients with age above 65 years and previous history of comorbidities in electronic health records for diabetes, hypertension, heart failure, stroke, cancer chemotherapy or immunodeficiency, were excluded from case group.

2.2. DNA extraction and ACE genotyping

Total genomic DNA was isolated using standard salting-out method (MWer et al., 1998). The quality and quantity of the purified DNA samples were evaluated by Nano-Drop 2000™ spectrophotometer (Thermo Fisher Scientific, USA). The extracted genomic DNA samples were stored at -20°C until genotyping.

PCR technique was used to investigate the insertion/deletion polymorphism of ACE gene. The PCR reaction volume was 10 μl and each reaction consisted of: 5 μl of PCR MasterMix 2× (Yektatajhiz, Iran), 0.4 μl genomic DNA sample, 0.2 μl (10 pmol/μl) of forward primer (5’-CTGGAGACCCATCCCATCTCCTTCT-3’), 0.2 μl (10 pmol/μl) of reverse primer (5’-GATTGGCCATCATCGTTCAGAT-3’) and 4.2 μl distilled water. For each experiment, a blank was prepared by adding 0.4 μl of water instead of a template DNA. The amplification reactions were performed using ABI Veriti thermal cycler machine (Thermo Fisher Scientific, USA). The PCR program was carried out with initial denaturation step at 94°C for 5 min, followed by 30 amplification cycles (30 s at 94°C, 45 s at 59°C, and 30 s at 72°C) and a final extension at 72°C for 7 min. Electrophoresis on 2% agarose gels (SinaClon BioScience, Iran) containing 0.5 mg/L DNA gel stain (SinaClon BioScience, Iran) was used to separate the amplification products and the image of bands visualized under the UV light and captured by gel documentation system (Syngene, UK).

The genotype of each patient was detected based on PCR product band size on agarose gel electrophoresis. Accordingly, if a 287 bp fragment is inserted, the amplified product size is 490 bp, and if the fragment is deletion, the amplified band size is 190 bp. In the presence of both 490 and 190 bp bands, the patient has a heterozygous genotype (DI), and if only the 190 bp or only the 490 bp band is observed, the patient is homozygous for deletion mutation (DD) and insertion mutation (II) in the 287 bp fragment, respectively (Fig. 1). PCR-based genotyping was confirmed by sanger sequencing for some DNA samples.

2.3. Statistical analysis

SPSS software (version 25) was used in statistical analysis. Allele and genotype frequencies between case and control groups were compared for significance, using $\chi^2$ (Fisher’s Exact test). Odds ratio (OR) with 95% confidence intervals (CI) were used to describe the strength of association. The genotypes frequencies in study population were evaluated for concordance with Hardy Weinberg equilibrium using SNP Analyzer 2.0 software. Also, association between ACEI I/D polymorphism and COVID-19 severity were analyzed in recessive, dominant and codominant models by SNP Analyzer 2.0 software. All p-value of less than 0.05 was considered to show statistically significant results.

3. Results

The total number of patients participating in this study was 251. The control group consisted of 151 patients with a mean age of 38.39 ± 11.84 and patients in this group had mild symptoms. The case group consists of 100 patients with severe to critical symptoms with a mean age of 46.35 ± 10.24. The percentage of male patients participated in the control and case groups is 61% and 55%, respectively.

Regarding to the ACEI gene I/D polymorphism, there were three genotypes (DD, II, and DI) among the study population. The frequency of genotypes and alleles in the control and case groups was shown in Table 1. The D allele had more frequency in the case and control groups and in whole study population. Regarding genotypes, DI genotype was more frequent in case and control groups in all COVID-19 patients.

The statistical analysis of the results showed a significant difference (p-value = $4 \times 10^{-2}$) between the distribution of ACE genotypes between the case and control groups. The frequency of II genotypes did not show any significant difference (p-value = $6 \times 10^{-1}$) between case and control groups. But the frequency of DD genotype in the case group showed a significant increase (p-value = $1 \times 10^{-4}$) in comparison with the control group. Also, the frequency of DI genotype decreased from 57% in the control group to 45% in the case group (p-value = $4 \times 10^{-2}$). Also, both I and D alleles showed significant differences between case and control groups.

The frequency distribution of ACE genotypes in case and control groups as well as in the all COVID-19 patient were in accordance with Hardy-Weinberg equilibrium (Table 1). Risk assessment for the ACE gene in recessive, dominant, and co-dominant inheritance models showed that ACEI I/D polymorphism was associated with the severe form of COVID-19 disease in both recessive (p-value = 0.013) and co-dominant (p-value = 0.041) models (Table 2).

4. Discussion

Global experience about COVID-19 infection showed that it cannot be a simple respiratory viral infection and there is a complex pathophysiology behind its severe presentations. Several investigations have
shown that disturbance of the renin-angiotensin (RAS) system balance is involved in the clinical complications of COVID-19 patients (Wiese et al., 2020; Gemmati et al., 2020b). Abnormal changes in the ACE1/ACE2 balance, involves in the of several medical problems such as heart failure, thrombotic disorders, nephropathy and severe acute respiratory distress (Haznedaroğlu, 2020; Xiao et al., 2020). The I/D polymorphism in ACE1 gene can influence on the ACE1 level in both blood circulation and tissue. It has been shown that the D allele in this polymorphism, is associated with higher ACE1 activity and it is estimated that about 60% of the ACE1 levels be determined by the ACE1 I/D polymorphism (Tiret et al., 1992). Indeed, previous investigations have been shown that in individuals with DD genotype have double levels of ACE1 activity in comparison with II genotype (Rigat et al., 1990b).

According to the contribution of ACE1 in RAS system and pathophysiology of COVID-19 complications in one hand and the influence of ACE1 gene I/D polymorphism in ACE1 level in another hand, in the present study, we tried to determine the role of ACE I/D polymorphisms in the severity of symptoms in COVID-19 patients. The results of our study showed that the risk of developing severe COVID-19 disease in

### Table 1

| Genotypes and alleles frequencies of the study population, p-values, odds ratio (OR) and 95% confidence intervals (95% CI). |
|---------------------------------------------------------------|
| Genotypes | Alleles | Hardy-Weinberg equilibrium (p-value) |
| | II | DI | DD | I | D |
| Control group | 30 (19.9) | 87 (57.6) | 34 (22.5) | 147 (48.7) | 155 (51.3) | 0.059 |
| n = 151 | 18 (11.9) | 45 (29.3) | 37 (24.2) | 81 (50.6) | 119 (49.4) | 0.507 |
| Case group | 48 (19.2) | 132 (52.8) | 71 (28.2) | 228 (45.4) | 274 (54.6) | 0.336 |
| n = 251 | 6 x 10^-1 | 4 x 10^-2 | 1 x 10^-2 | 1 x 10^-4 | 1 x 10^-3 | 0.465 |
| p-value | 0.078 | 0.592 | 2.094 | 0.342-0.631 | 0.526-0.920 | 0.465 |

*: Sample number.

### Table 2

Analysis of ACE I/D genotypes association with COVID-19 disease severity under three different inheritance models. p-values, odds ratio (OR) and 95% confidence intervals (95% CI).

| Inheritance models | Recessive (DD vs. DI + II) | Co-dominant (DI vs. II + DD) | Dominant (DD + DI vs. II) |
|--------------------|---------------------------|-----------------------------|----------------------------|
| p-value            | 0.013                     | 0.041                       | 0.713                      |
| OR (95% CI)        | 2.021 (1.157-3.529)       | 1.814 (0.859-3.829)         | 1.129 (0.591-2.16)         |

Fig. 1. A) Diagram of PCR for ACE1 genotyping. The amplified band by two forward (F) and reverse (R) primers, if 287 bp fragment inserted, PCR product is 490 bp which represents the I allele, and if the 287 bp fragment is deleted, 190 bp will be obtained, which represents the D allele. B) Electropherogram PCR product. Line M: 100 bp ladder. Line 1 shows DI genotype, line 2 shows DD genotype and line 3 is II genotype.

shown that disturbance of the renin-angiotensin (RAS) system balance is involved in the clinical complications of COVID-19 patients (Wiese et al., 2020; Gemmati et al., 2020b). Abnormal changes in the ACE1/ACE2 balance, involves in the of several medical problems such as heart
patients with D allele (p-value $= 1 \times 10^{-2}$) and DD genotype (p-value $= 1 \times 10^{-2}$) was significantly higher than two other genotypes (DI, II). Also, the risk of severe form of COVID-19, was increased 2-folds in individuals with DD genotype (OR $= 2.004$, 95%CI $= 1.147–3.499$) and our results showed that ACE1 D/I variant was inherited under recessive or co-dominant inheritance patterns. Our findings in Iranian patients are in concordance with the results of other studies in Indian and Spanish populations (Verma et al., 2021; Gómez et al., 2020). In another investigation on Italian patients, in spite of limited sample size (26 ICU-admitted COVID-19 patients), the results were consistent with our findings (Anunnziata et al., 2020). Conversely, an investigation about ACE1 D/I association with COVID-19 risk on Czechs (as a west Slavic ethnic group in central Europe), showed un concordant results with our findings (Hubacek et al., 2021). This study reported that the frequency of II genotype was significantly higher in symptomatic COVID-19 patients. It is considerable that the participants in this study consisted of asymptomatic and symptomatic (without hospitalization) COVID-19 patients. Although the reason of this discrepancy is unclear now, but it seems that lack of severe to critical form of COVID-19 in the study population along with ethnicity background can be influential.

Comparison of ACE1 genotypes frequencies data in different ethnicities with reported COVID-19 cases and mortality rate, showed that the frequency of ACE1 II genotype was negatively correlated with the number of SARS-CoV-2 infected cases and number of deaths due to SARS-CoV-2 infection (Yamamoto et al., 2020). Our findings showed that the allele frequency of I allele was significantly higher in control group and it can be a protective allele, but the II genotype had not as association with asymptomatic or mild form of COVID-19 infection in our study population.

5. Conclusion

The results of our study showed that ACE1 DD genotype is associated with the severity of COVID-19 in Iranian patients and it can double the risk of severe form of the COVID-19 disease. Also, our findings showed that the II genotype did not play a significant role against the severe form of COVID-19 disease. Thus, determining ACE genotype can help in prediction of COVID-19 infection progression to a severe form as a background genetic risk factor. Identifying the role of genetic factors on susceptibility to severe COVID-19 disease can play an important role in the better management of patients and personalized medicine as well as the development of better treatment strategies for these high-risk groups. The advantage of our study was the exclusion of patients with known risk factors for severe form of COVID-19 infection from case group to better evaluation of the influence of genetic background on disease presentation. Further studies with larger sample sizes in other populations are needed to confirm the role of ACE I/D polymorphism in SARS-CoV-2 infection as well as to identify other genetic risk-factors.

Author contributions

J.S.L conducted the experiments and wrote the manuscript. and J.S.R contributed in laboratory works. M.S.Y performed statistical analysis and data interpretation. P.I. designed the study, supervised the project and revised the manuscript. All the authors reviewed and approved the final manuscript.

Declaration of Competing Interest

No potential conflict of interest was reported by the authors.

Acknowledgements

This study was a part of a M.Sc. thesis supported by Tehran University of Medical Sciences (Tehran, Iran; grant No: 49587). We would like to thank Ms. Masoumeh Amini for her technical assistance.

References

Anunnziata, A., Coppola, A., Lamza, M., Simioli, F., Imitazione, P., Pepe, N., Maddaloni, V., Aripaldi, I., Fingi, J., et al. (2020). ACE DD polymorphism in severe COVID-19. J. Transl. Sci. 7 (1), 10-15761.

Crisan, D., Carr, J., 2000. Angiotensin I-converting enzyme: genotype and disease associations. J. Mol. Diagn. 2 (3), 105-115.

Donoghue, M., Hsieh, F., Barrowes, K., Godbout, K., Gusenlin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jayaseelan, R., Breitbart, R., 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87 (5), e1-e9.

Gao, J., Ham, D., Dong, X., Zheng, J., Gu, S., Azar, A., Arzuk, D., Gan, H., Sun, Y., Fu, W., Li, W., Liang, H.L., 2021. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76 (2), 428-455.

Gemmatri, D., Bramanti, B., Serino, M.L., Secchiero, P., Zauli, G., Tisato, V. 2020a. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X chromosome in females be protective against SARS-CoV-2 compared to the single X chromosome in males? Int. J. Mol. Sci. 21 (10), 3474.

Gemmatri, D., Bramanti, B., Serino, M.L., Secchiero, P., Zauli, G., Tisato, V. 2020b. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X chromosome in females be protective against SARS-CoV-2 compared to the single X chromosome in males? Int. J. Mol. Sci. 21 (10), 3474.

Gómez, J., Albaceta, G.M., García-Clemente, M., López-Larrea, C., Ámado-Rodríguez, L., López-Alonso, I., Hermida, T., Enríquez, A.I., Herrero, P., Melón, S., Alvarez-Arigielle, M.E., 2020. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene 762, 145102.

Hazenadoru, L.C., 2020. Immunogenomic phases of COVID-19 and appropriate clinical management. Lancet Microbe 1 (7) (p.e278).

Hubacek, A.J., Dusel, L., Majek, O., Adamek, V., Cervinkova, T., Dlouha, D., Adamkova, Adamkova, 2021. ACE I/D polymorphism in Czech first-wave SARS-CoV-2-positive survivors. Clin. Chim. Acta 519, 206-209.

Kachuri, L., Francis, S.S., Morrison, M., Wrentd, G.A., Bosse, Y., Cavadza, T.B., Rashkin, S. R., Ziv, E., Witte, J.K., 2020. The landscape of host genetic factors involved in immune response to common viral infections. medRxiv 20088054. https://doi.org/10.1101/2020.05.01.20088054.

Weber, S., Dykes, D., Polskey, H.J., 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (3), 1215.

Patel, S., Rauf, A., Khan, H., Abu-Izneid, T., 2017. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomedphacore. 94, 317-325.

Rigat, B., Hubert, C., Albenac-Gelas, F., Cambien, F., Corvol, P., Soubrrier, F., 1990a. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86 (4), 1343-1346.

Rigat, B., Hubert, C., Albenac-Gelas, F., Cambien, F., Corvol, P., Soubrrier, F., 1990b. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86 (4), 1343-1346.

Sancho-Bru, N., Sampaio, W.O., Alzamora, A.C., Motta-Santos, D., Alenina, N., Rader, M., Campagnole-Santos, M.J., 2018. The ACE2/angiotensin (1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin (1–7). Physiol. Rev. 98 (1), 505-553.

Schrur, T.G., 2020. Host genetic factors and susceptibility to SARS-CoV-2 infection. Am. J. Med. Genet. B 2 (5), e24497.

Smatni, M.K., Al-Sarraj, Y.A., Albagha, O., Yassine, H.M., 2020. ACE1 I/D polymorphism in Czech first wave SARS-CoV-2 patients. PLoS One 15 (1) (p.e023622). https://doi.org/10.1371/journal.pone.023622.

Tikhonirova, V.E., Kost, O.A., Smatti, M.K., Al-Sarraj, Y.A., Albagha, O., Yassine, H.M., 2020. Host genetic variants potentially associated with SARS-CoV-2: a multi-population analysis. Front. Genet. 11, 578523. https://doi.org/10.3389/fgene.2020.578523.

Vay, E., Witte, J.K., 2020. The landscape of host genetic factors involved in immune response to common viral infections. medRxiv 20088054. https://doi.org/10.1101/2020.05.01.20088054.

Wiser, S., Canfield, A., 2021. ACE I/D polymorphism in severe COVID-19 patients. J. Transl. Sci. 7 (1), 10-15761.

Wu, A., Peng, Y., Huang, B., Ding, X., Wang, X., Niu, P., et al., 2020. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 27 (3), 325–328.

Xue, L., Tanigawa, H., Mise, M., 2020. ACE: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses 12 (5), 491.

Yamamoto, N., Ariumi, Y., Nishida, N., Yamamoto, R., Bauer, G., Gojobori, T., Shimotohno, K., Mizokami, M., 2020. SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene 758, 144944.

Yamamoto, N., Yamamoto, R., Ariumi, Y., Mizokami, M., Shimotohno, K., Yoshikura, H., 2021. Does genetic predisposition contribute to the exacerbation of COVID-19
symptoms in individuals with comorbidities and explain the huge mortality disparity between the East and the West? Int. J. Mol. Sci. 22 (9), 5000.

Yanes-Lane, M., Winters, N., Fregonese, F., Bastos, M., Perlman-Arrow, S., Campbell, J. R., et al., 2020. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS One 15 (11), e0241536.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., Chen, H.D., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (7798), 270–273.